Vietnamese crab exporter

Zydus Cadila gets DCGI nod for Phase 3 trial of repurposed drug to treat Covid-19

The drug, Pegylated Interferon alpha-2b, 'PegiHepTM', is an approved drug that been in use since 2001 and is now being re-purposed to treat Covid-19 patients.

Advertisement
Zydus Cadila gets DCGI nod for Phase 3 trial of repurposed drug to treat Covid-19
Zydus Cadila has got the approval to start phase 3 trials of coronavirus vaccine on patients (Photo: Reuters)

Gujarat-based drug manufacturer Zydus Cadila today said it has received approval from the Drugs Controller General of India (DCGI) to conduct Phase 3 clinical trials on its re-purposed drug that it hopes to use for Covid-19 treatment.

The drug, Pegylated Interferon alpha-2b, 'PegiHepTM', is an approved drug that been in use since 2001 and is now being re-purposed to treat Covid-19 patients.

advertisement

Zydus Cadila said the Phase 3 trials will start in December and will be conducted on 250 patients across 20-25 centres in India.

"The Phase II clinical trials study established the early safety, efficacy and tolerability of PegiHep TM and has indicated that Pegylated Interferon alpha-2b has statistical clinical beneficial impact on patients suffering from moderate Covid-19 by reducing their viral load. This helps in better disease management, such as by reducing duration of oxygen support," Zydus Cadila said in a statement.

It added that a single dose therapy will improve compliance and also make it "highly affordable" for patients.

Dr Sharvil Patel, Managing Director, Cadila Healthcare Ltd., said, "We are encouraged by the results of Phase II study of Pegylated Interferon alpha 2-b which has shown the potential to reduce virus titres when given earlier in the disease. Our efforts are to look at possible treatment options to fight Covid-19 which are safe, can be administered easily and also reduce the disease burden."

Speaking about the Phase 2 trials, the drug manufacturer said these trials were open-label, randomised, comparator controlled study, and involved 40 adult patients with moderate Covid-19.

"Ninety-five per cent subjects in the test arm who received a single dose of PegiHepTM along with the Standard Of Care (SOC), became virus free as assessed by RT-PCR on Day 14 and showed a statistically significant clinical improvement over the patients in the reference arm, who received only the standard of care and where only 68 per cent patients showed an improvement in clinical symptoms and became RT-PCR negative," the statement said.

Zydus Cadila is also conducting a similar Phase 2 trial in Mexico. The company is also working with the USFDA to open an Investigational New Drug (IND) application for Pegylated Interferon alpha-2b in order to initiate appropriate clinical trials in US.

Pegylated Interferon alpha-2b is not a new therapy. It was first approved internationally in 2001 and is also included in the World Health Organisation's Essential Medicines List.

Zydus Cadila's Pegylated Interferon alpha-2b, PegiHepTM, was originally approved for Hepatitis C and was launched in the Indian market in 2011.

Gopi Maniar Ghanghar

Gopi Maniar Ghanghar, Deputy Editor AAJTAK Gujarat Bureau, she looks after the entire Gujarat and associated with AAJTAK & India Today group since 2002. She is Editor of Gujarat Tak a digital plat form of TVToday Group, she successfully run it and shown her vast knowledge of regional politics & cultural in Gujart tak. she heads a team of journalist to get best output for Gujarat. She is contributing in TV Today network's all Digital platform.

Her vast experience in Gujarat Politics and catching the pulse of Gujarat is unparallel in present time. She started her reporting carrier from 2001 Gujarat earth quake and covered 2002 riots. She has witness the journey of Gujarat politics transfer of power from Keshubhai to Narendra Modi, and from three terms of Chief Minister Narendra Modi. Also huge transformation from Narendra Modi's Hinduva to Narendra Modi's vikas agenda, from CM to PM, and rise of power of Mr.Narendra Modi and BJP.

Fake encounter stories covered by her became most popular. It was like a milestone in the industry and created a huge wave in Journalism as well as political circle. Amit shah's court case being fugitive from Gujarat taking asylum in centre and rising back with more strength and power responsibility in his own party. She has witnessed all this events as frame by frame throughout her carrier as journalist. Also, the transformation of Amit Shah from state politics to nation politics. state MoS to HM of the country.

In a religious country like India , where god mans are treated very next to the God, they have never been questioned. Hence, they think they are above the law of land. Her constant thrives for truth in 2008s Dipesh Abhishek Murder case of Asharam Asaram concluded the God man found guilty and was questioned for the first time and it resulted in his severing in Jail. While reporting this case she stood firm against the goon of God Man Asaram, even though she was brutally beaten in the process of covering the truth and leading the story ahead to it's final judgment. This is the impact of Gold standard Journalism.

Gopi Maniar Ghanghar Born in Ahmedabad Gujarat, she studied in St. Xavier's collage Ahmedabad and did her Masters in Journalism and Mass Communication from Gandhian institute Gujarat Vidhyapith. She was awarded twice with INDIA TODAY CHAIRMAN's award for best coverage for Gujarat Election in 2017 and web stories for 2018 and many others award from Gujarat as well.

READ MORE